| Management target | Revenue 20.0% Q1FY22 to Q1FY27 |
|---|
| Revenue growth | 24% YoY Consolidated |
|---|---|
| Margins | EBITDA margin up 226bps to 32% |
| Demand visibility | Strong growth in pathology vials (+22% YoY) |
| Management confidence | High; citing 'Routine to Remarkable' strategy |
Growth
Pathology revenue grew 26% YoY; standalone revenue at 226 Cr. EBITDA grew 34% YoY with margins improving to 32%.
Outlook
Expanding specialty offerings (Genomics, NIPT) and strengthening B2B franchise network. Capex of ~250 Cr over the last 5 years.
Risks
Radiology revenue declined 4% YoY due to strategic exits from non-profitable centers.
Last quarter's promises, checked
Delivered
- Guided mid-to-high teens revenue growth → delivered 24% (= BEAT)
- Guided 500 new franchisees per quarter → delivered 900+ (= BEAT)
- Guided 40 labs → delivered 44 labs (= BEAT)
Partly delivered
- Guided radiology consolidation for bottom-line improvement → revenue still declining 4% (= PARTIAL)
Missed
- Guided 34% normalized EBITDA margin → delivered 32% (= MISS)
Investor Presentation filed with BSE, NSE: THYROCARE. Summary written with AI assistance from the document.
Thyrocare Technologies Ltd: key numbers
- Share price
- ₹566.85
- Market cap
- ₹9,022 Cr
- Revenue (annual)
- ₹829.0 Cr
- Net profit (annual)
- ₹163.0 Cr
- P/E (TTM)
- 51.2×Sector 57.8×
- Promoter holding
- 60.92%+0.00% QoQ
- FII holding
- 5.43%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Thyrocare Technologies Ltd
All →Thyrocare Technologies Employee Stock Options
Thyrocare Technologies Limited has granted 1,92,000 employee stock options to eligible employees under the company's approved stock option scheme.
Thyrocare Technologies Merger & Restructuring Worth ₹141.4 Cr
Thyrocare's board approved sale of 100% in Nueclear Healthcare to Trovera for ~₹141.40 Crore. The move exits radiology to refocus on core pathology business.
- Value
- ₹141.4 Cr
- Execution
- On or before November 30, 2026
Thyrocare Technologies Share Pledge
API Holdings, successor to promoter Docon, released a full pledge over 7.95 crore Thyrocare shares after NCD redemption. No Docon shares remain encumbered.
Thyrocare Technologies Acquisition
API Holdings Limited reported an exempt acquisition of 8.12 crore shares (51.02%) of Thyrocare Technologies Limited, pursuant to the amalgamation of Docon Technologies Private Limited.
Thyrocare Technologies Promoter Buying (Off-Market)
API Holdings acquired 8,12,00,000 shares (51.02%) of Thyrocare Technologies via a NCLT-approved scheme of amalgamation. The transfer resulted from the merger of Docon Technologies into API Holdings.
- Promoter stake change
- +51.02%
Thyrocare Technologies Earnings Call Transcript: Key Takeaways
Thyrocare Q1 FY27: Consolidated revenue grew 24.3% YoY to INR 240 Cr, EBITDA margin expanded to 32.2%. Strategy shifts toward specialty diagnostics.
- Call
- Guides 18% growth